Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

329.97 +4.35 (+1.34%)
Streaming Delayed Price Updated: 10:23 AM EDT, Jun 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Executives Sell Over $100M Of 4 Stocks
Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Executives Sell Around $96M Of 5 Stocks
US stocks closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
7 Top Stocks to Buy And Watch Today
Dow Jones leaders Chevron (CVX) and Merck (MRK) — in addition to Livent (LTHM), Eli Lilly (LLY), Northrop Grumman (NOC), 
Via Best Stocks
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly Stock Breaks Out To Another Record High As Cancer Data Looms
The company will unveil test results for three cancer drugs in June. 
Via Investor's Business Daily
Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Eli Lilly
Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT... 
Via Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Executives Sell Around $207M Of 5 Stocks
Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
 
Via Benzinga
S&P 500 Falls For 7th Consecutive Week Amid Ongoing Inflation, Federal Reserve Rate Hike Fears
U.S. indices rebounded off session lows Friday to finish mixed. Markets at large traded lower this week amid a continued sell off in stocks following recent earnings from retail companies. Concerns... 
Via Benzinga
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
 
Via Benzinga
Why Eli Lilly' Shares Are Trading Higher Today
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Via Benzinga
Why Eli Lilly Shares Are Rising Today
Eli Lilly And Co (NYSE: LLY) shares are trading higher by 3.58% at $296.48 after the company announced the CHMP has issued a positive opinion for OLUMIANT for the treatment of adults with severe... 
Via Benzinga
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
A confirmed market uptrend is reeling as inflation's pain bites. 
Via Investor's Business Daily
Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19
 
Via Benzinga
PepsiCo And 3 Other Stocks Insiders Are Selling
US crude oil futures traded lower, dropping around 1% on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach... 
Via iCrowdNewswire
Veterinary Antibiotics Market Research Insight 2022| Key Players are Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Crystal Pharma, Dechra Pharmaceuticals PLC, Huvepharma AD, Eli Lilly Company, Elanco, Merck & Co., Inc., Sanofi S.A., Ve
Via iCrowdNewswire
Exposures COVID-19
Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout. 
Via Investor's Business Daily
How Is The Market Feeling About Eli Lilly?
Eli Lilly's (NYSE:LLY) short percent of float has risen 6.85% since its last report. The company recently reported that it has 6.22 million shares sold short, which is 0.78% of... 
Via Benzinga
Five Ways To Play A Stock Market Reprieve
Eli Lilly and Albemarle lead 5 stocks that may be poised to lead the way higher. 
Via Investor's Business Daily
Check Out What Whales Are Doing With LLY
A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades. 
Via Benzinga
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Arkansas has accused Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and three of the largest pharmacy benefit... 
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
Heart Failure Treatment Offers Hope to Diabetics
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.